Study type: Medical/biological study (experimental study)

Microwave facilitation of methylatropine antagonism of central cholinomimetic drug effects. med./bio.

Published in: Radiat Res 1986; 105: 328-340

Aim of study (acc. to editor)

Employment of a pharmacologic assay designed specifically to assess small alterations in site-specific areas of the CNS. The assay employs centrally acting cholinergic agonists (pilocarpine and oxotremorine). Blockade of this central activity is produced by the muscarinic antagonist methylatropine (a compound that is thought not to cross the blood-brain barrier and that has normally no measurable CNS activity at the doses employed in this study). It should be investigated if a change in methylatropine availability to central muscarinic receptors occurs following microwave exposure.

Endpoint

Exposure

Exposure Parameters
Exposure 1: 2.45 GHz
Modulation type: CW
Exposure duration: continuous for 10 min

Exposure 1

Main characteristics
Frequency 2.45 GHz
Type
Charakteristic
  • guided field
Exposure duration continuous for 10 min
Modulation
Modulation type CW
Exposure setup
Exposure source
Chamber R-band waveguide/ 5.4 cm high x 10.9 cm wide x 27 cm long
Setup Animals kept unrestrained in a styrofoam cage/ 5 cm high x 9 cm wide x 11 cm long located in the waveguide
Parameters
Measurand Value Type Method Mass Remarks
power density 100 W/m² effective value measured - corresponding SAR: 23.7 W/kg calculated according to Dewar-Flask calorimeter technique

Exposed system:

Methods Endpoint/measurement parameters/methodology

Investigated system:
Investigated organ system:
Time of investigation:
  • after exposure

Main outcome of study (acc. to author)

A highly sensitive pharmacological assay system has been devised that demonstrates an increase in the central activity of an agent normally excluded by the blood-brain barrier (BBB). The sensitivity and the specificity are supportive of an alteration in BBB function induced by microwave irradiation.

Study character:

Study funded by